361 related articles for article (PubMed ID: 24061981)
1. [Biomarkers of predicting response to neoadjuvant chemoradiotherapy in esophageal cancer].
Fu JH
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Sep; 16(9):805-10. PubMed ID: 24061981
[TBL] [Abstract][Full Text] [Related]
2. Predicting response to neoadjuvant therapy in esophageal cancer.
Vallböhmer D; Brabender J; Grimminger P; Schröder W; Hölscher AH
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1449-55. PubMed ID: 21929318
[TBL] [Abstract][Full Text] [Related]
3. [New trends in neoadjuvant chemoradiotherapy for locally-advanced esophageal cancer: esophagectomy--is it necessary?].
Fujita H; Sueyoshi S; Tanaka T; Toh U; Mine T; Sasahara H; Shirouzu K; Yamana H; Toda Y; Hayabuchi N
Gan To Kagaku Ryoho; 2000 Nov; 27(13):2016-22. PubMed ID: 11103231
[TBL] [Abstract][Full Text] [Related]
4. Preoperative therapy for esophageal cancer.
Ku GY; Ilson DH
Gastroenterol Clin North Am; 2009 Mar; 38(1):135-52, ix. PubMed ID: 19327572
[TBL] [Abstract][Full Text] [Related]
5. The current evidence in support of multimodal treatment of locally advanced, potentially resectable esophageal cancer.
Zacherl J
Dig Dis; 2014; 32(1-2):171-5. PubMed ID: 24603404
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemoradiotherapy for locally advanced esophageal cancer: experience at a single institution.
Malaisrie SC; Untch B; Aranha GV; Mohideen N; Hantel A; Pickleman J
Arch Surg; 2004 May; 139(5):532-8; discussion 538-9. PubMed ID: 15136354
[TBL] [Abstract][Full Text] [Related]
7. The effectiveness of planned esophagectomy after neoadjuvant chemoradiotherapy for advanced esophageal carcinomas.
Kato H; Fukuchi M; Manda R; Faried A; Takita J; Nakajima M; Miyazaki T; Sohda M; Fukai Y; Masuda N; Tsukada K; Kuwano H
Anticancer Res; 2004; 24(6):4091-6. PubMed ID: 15736457
[TBL] [Abstract][Full Text] [Related]
8. Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer.
Vallböhmer D; Kuhn E; Warnecke-Eberz U; Brabender J; Hoffmann AC; Metzger R; Baldus SE; Drebber U; Hoelscher AH; Schneider PM
Pharmacogenomics; 2008 Jun; 9(6):681-90. PubMed ID: 18518847
[TBL] [Abstract][Full Text] [Related]
9. Preoperative treatment of locally advanced esophageal carcinoma (Review).
Orditura M; Galizia G; Fabozzi A; Lieto E; Gambardella V; Morgillo F; Del Genio GM; Fei L; Di Martino N; Renda A; Ciardiello F; De Vita F
Int J Oncol; 2013 Dec; 43(6):1745-53. PubMed ID: 24100679
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities.
Mariette C; Piessen G; Triboulet JP
Lancet Oncol; 2007 Jun; 8(6):545-53. PubMed ID: 17540306
[TBL] [Abstract][Full Text] [Related]
11. Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients.
Hoeppner J; Zirlik K; Brunner T; Bronsert P; Kulemann B; Sick O; Marjanovic G; Hopt UT; Makowiec F
J Surg Oncol; 2014 Mar; 109(3):287-93. PubMed ID: 24277235
[TBL] [Abstract][Full Text] [Related]
12. Present status and progress of neoadjuvant chemoradiotherapy for esophageal cancer.
Liu J; Yue J; Xing L; Yu J
Front Med; 2013 Jun; 7(2):172-9. PubMed ID: 23681891
[TBL] [Abstract][Full Text] [Related]
13. REG I expression predicts long-term survival among locally advanced thoracic squamous cell esophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by esophagectomy.
Motoyama S; Sugiyama T; Ueno Y; Okamoto H; Takasawa S; Nanjo H; Watanabe H; Maruyama K; Okuyama M; Ogawa J
Ann Surg Oncol; 2006 Dec; 13(12):1724-31. PubMed ID: 17009160
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer.
Kim DW; Blanke CD; Wu H; Shyr Y; Berlin J; Beauchamp RD; Chakravarthy B
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):397-404. PubMed ID: 17097833
[TBL] [Abstract][Full Text] [Related]
15. [Salvage surgery: cancer of the esophagus].
Triboulet JP
Bull Cancer; 2011 Jan; 98(1):73-8. PubMed ID: 21300611
[TBL] [Abstract][Full Text] [Related]
16. Quantifying the benefit of a pathologic complete response after neoadjuvant chemoradiotherapy in the treatment of esophageal cancer.
Scheer RV; Fakiris AJ; Johnstone PA
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):996-1001. PubMed ID: 20584580
[TBL] [Abstract][Full Text] [Related]
17. Role of neoadjuvant therapy for esophageal adenocarcinoma.
Ku GY; Ilson DH
Surg Oncol Clin N Am; 2009 Jul; 18(3):533-46. PubMed ID: 19500742
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemoradiotherapy for resectable oesophageal and gastro-oesophageal junction cancer--do we need another randomised trial?
Hingorani M; Crosby T; Maraveyas A; Dixit S; Bateman A; Roy R
Clin Oncol (R Coll Radiol); 2011 Dec; 23(10):696-705. PubMed ID: 21684129
[TBL] [Abstract][Full Text] [Related]
19. Cyclin D1 is a possible predictor of sensitivity to chemoradiotherapy for esophageal squamous cell carcinoma.
Samejima R; Kitajima Y; Yunotani S; Miyazaki K
Anticancer Res; 1999; 19(6C):5515-21. PubMed ID: 10697609
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant therapy of esophageal cancer.
Ilson DH; Bains M; Ginsberg RJ; Kelsen DP
Surg Oncol Clin N Am; 1997 Oct; 6(4):723-40. PubMed ID: 9309090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
